论文部分内容阅读
本文对92例肝疾病(包括肝硬化、原发性肝癌、慢性活动性肝炎)患者进行血清胰蛋白酶的抑制能力(简称STIC)测定,以间接反映出血清α_1-抗胰蛋白酶活性水平,并与30例健康对照组比较观察。结果表明,两组间无显著性差异。
In this paper, 92 cases of liver disease (including cirrhosis, primary liver cancer, chronic active hepatitis) in patients with serum trypsin inhibition (STIC) determination to indirectly reflect the level of serum α 1-antitrypsin activity, and with 30 cases of healthy control group were observed. The results showed no significant difference between the two groups.